R1/ 1

#### 1 Improvement in Delivery of Ischemic Stroke Treatments but Stagnation of Clinical

## 2 Outcomes in Young Adults in South Korea

3

4	Jonguk Kim, MD <sup>1</sup> , Jun Yup Kim, MD <sup>1</sup> , Jihoon Kang MD, PhD <sup>1</sup> , Beom Joon Kim, MD, PhD <sup>1</sup> ,
5	Moon-Ku Han, MD, PhD <sup>1</sup> , Jeong-Yoon Lee, MD <sup>1</sup> , Tai Hwan Park, MD, PhD <sup>2</sup> , Ji Sung Lee,
6	PhD <sup>3</sup> , Keon-Joo Lee, MD <sup>4</sup> , Joon-Tae Kim, MD, PhD <sup>5</sup> , Kang-Ho Choi, MD, PhD <sup>5</sup> , Jong-Moo
7	Park, MD, PhD <sup>6</sup> , Kyusik Kang, MD, PhD <sup>7</sup> , Soo Joo Lee, MD, PhD <sup>8</sup> , Jae Guk Kim, MD <sup>8</sup> , Jae-
8	Kwan Cha, MD, PhD <sup>9</sup> , Dae-Hyun Kim, MD, PhD <sup>9</sup> , Kyungbok Lee, MD, PhD <sup>10</sup> , Jun Lee,
9	MD, PhD <sup>11</sup> , Keun-Sik Hong, MD, PhD <sup>12</sup> , Yong-Jin Cho, MD, PhD <sup>12</sup> , Hong-Kyun Park, MD <sup>12</sup> ,
10	Byung-Chul Lee, MD, PhD <sup>13</sup> , Kyung-Ho Yu, MD, PhD <sup>13</sup> , Mi-Sun Oh, MD <sup>13</sup> , Dong-Eog Kim,
11	MD, PhD <sup>14</sup> , Wi-Sun Ryu, MD, PhD <sup>14</sup> , Jay Chol Choi, MD, PhD <sup>15</sup> , Jee-Hyun Kwon, MD,
12	PhD <sup>16</sup> , Wook-Joo Kim, MD <sup>16</sup> , Dong-Ick Shin, MD, PhD <sup>17</sup> , Kyu Sun Yum, MD <sup>17</sup> , Sung Il
13	Sohn, MD, PhD <sup>18</sup> , Jeong-ho Hong, MD, PhD <sup>18</sup> , Sang-Hwa Lee, MD, PhD <sup>19</sup> , Juneyoung Lee,
14	PhD <sup>20</sup> , Philip B. Gorelick, MD MPH <sup>21</sup> and Hee-Joon Bae, MD, PhD <sup>1</sup>
15	
15 16	<sup>1</sup> Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
	<sup>1</sup> Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea <sup>2</sup> Department of Neurology, Seoul Medical Center, Seoul, Korea
16	
16 17	<sup>2</sup> Department of Neurology, Seoul Medical Center, Seoul, Korea
16 17 18	<sup>2</sup> Department of Neurology, Seoul Medical Center, Seoul, Korea <sup>3</sup> Clinical Research Center, Asan Medical Center, Seoul, Korea
16 17 18 19	<ul> <li><sup>2</sup>Department of Neurology, Seoul Medical Center, Seoul, Korea</li> <li><sup>3</sup>Clinical Research Center, Asan Medical Center, Seoul, Korea</li> <li><sup>4</sup>Department of Neurology, Korea University Guro Hospital, Seoul, Korea</li> </ul>
16 17 18 19 20	<ul> <li><sup>2</sup>Department of Neurology, Seoul Medical Center, Seoul, Korea</li> <li><sup>3</sup>Clinical Research Center, Asan Medical Center, Seoul, Korea</li> <li><sup>4</sup>Department of Neurology, Korea University Guro Hospital, Seoul, Korea</li> <li><sup>5</sup>Department of Neurology, Chonnam National University Hospital, Gwangju, Korea</li> </ul>
16 17 18 19 20 21	<ul> <li><sup>2</sup>Department of Neurology, Seoul Medical Center, Seoul, Korea</li> <li><sup>3</sup>Clinical Research Center, Asan Medical Center, Seoul, Korea</li> <li><sup>4</sup>Department of Neurology, Korea University Guro Hospital, Seoul, Korea</li> <li><sup>5</sup>Department of Neurology, Chonnam National University Hospital, Gwangju, Korea</li> <li><sup>6</sup>Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu,</li> </ul>
<ol> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> <li>21</li> <li>22</li> </ol>	<ul> <li><sup>2</sup>Department of Neurology, Seoul Medical Center, Seoul, Korea</li> <li><sup>3</sup>Clinical Research Center, Asan Medical Center, Seoul, Korea</li> <li><sup>4</sup>Department of Neurology, Korea University Guro Hospital, Seoul, Korea</li> <li><sup>5</sup>Department of Neurology, Chonnam National University Hospital, Gwangju, Korea</li> <li><sup>6</sup>Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea</li> </ul>

R1/ 2

26	<sup>9</sup> Department	of Neurology,	Dong-A	University	V Hospita	l, Busan,	Korea

- <sup>10</sup>Department of Neurology, Soonchunhyang University Hospital, Seoul, Korea
- <sup>11</sup>Department of Neurology, Yeungnam University Medical Center, Daegu, Korea
- <sup>29</sup> <sup>12</sup>Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea
- <sup>13</sup>Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea
- <sup>14</sup>Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
- 32 <sup>15</sup>Department of Neurology, Jeju National University Hospital, Jeju, Korea
- <sup>16</sup>Department of Neurology, Ulsan University Hospital, Ulsan, Korea
- <sup>17</sup>Department of Neurology, Chungbuk National University & Hospital, Cheongju, Korea
- <sup>18</sup>Department of Neurology, Keimyung University Dongsan Hospital, Daegu, Korea
- <sup>19</sup>Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital,
- 37 Chuncheon, Korea
- <sup>20</sup>Department of Biostatistics, Korea University, Seoul, Korea
- <sup>21</sup>Davee Department of Neurology, Northwestern University Feinberg School of Medicine,
- 40 Chicago, Illinois, USA
- 41
- 42 Corresponding author: Hee-Joon Bae, <u>braindocbae@gmail.com</u>, 82, Gumi-ro 173,
- 43 Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Korea.
- 44 Short title: Secular Trends in Young Adult Stroke
- 45 Word count: 6483
- 46
- 47

R1/ 3

## 48 Abstract

#### 49 Background

50	There is limited	l information on	the delivery	of acute stroke	therapies and seconda	ary
----	------------------	------------------	--------------	-----------------	-----------------------	-----

51 preventive measures and clinical outcomes over time in young adults with acute ischemic

52 stroke (AIS). This study investigated whether advances in these treatments improved

53 outcomes in this population.

#### 54 Methods

55 Using a prospective multicenter stroke registry in Korea, young adults (aged 18–50 years)

56 with AIS hospitalized between 2008 and 2019 were identified. The observation period was

57 divided into four epochs: 2008–2010, 2011–2013, 2014–2016, and 2017–2019. Secular

58 trends for patient characteristics, treatments, and outcomes were analyzed.

#### 59 **Results**

60 A total of 7,050 eligible patients (mean age 43.1; men 71.9%) were registered. The mean age 61 decreased from 43.6 to 42.9 years (Ptrend=0.01). Current smoking decreased, whereas obesity 62 increased. Other risk factors remained unchanged. Intravenous thrombolysis and mechanical 63 thrombectomy rates increased over time from 2008–2010 to 2017–2019 (9.5% to 13.8% and 64 3.2% to 9.2%, respectively; P<sub>trend</sub>'s<0.01). Door-to-needle time improved (P<sub>trend</sub><.001), but 65 onset-to-door and door-to-puncture time remained constant. Secondary prevention including 66 the administration of dual antiplatelets for noncardioembolic minor stroke (26.7% to 47.0%), 67 direct oral anticoagulants for atrial fibrillation (0.0% to 56.2%), and stating for large artery 68 atherosclerosis (76.1% to 95.3%) increased ( $P_{trend}$ 's<0.01). Outcome data were available from 69 2011. One-year mortality (2.5% in 2011–2013 and 2.3% in 2017–2019) and 3-month

- R1/ 4
- 70 modified Rankin scale scores 0-1 (68.3% to 69.1%) and 0-2 (87.6% to 86.2%) remained
- 1 unchanged. The one-year stroke recurrence rate increased (4.1% to 5.5%, P<sub>trend</sub>=0.04),
- altough the differnce was not significant after adjusting for sex and age.

## 73 Conclusion

- 74 Improvements in the delivery of acute stroke treatments did not necessarily lead to better
- 75 outcomes in young adults with AIS over the past decade, indicating a need for further
- 76 progress.
- 77

78

R1/ 5

# 79 Introduction

80	Young adults, commonly defined as individuals aged 18 to 50, constitute 10-15% of
81	the acute ischemic stroke (AIS) population. <sup>1</sup> Despite a reduction in the incidence of ischemic
82	stroke in high-income countries, there has been a worrisome increase among young adults,
83	particularly in developed countries. <sup>2</sup> Additionally, healthcare costs for young adults with
84	stroke are approximately 1.6 times higher than for older patients. <sup>3</sup> Therefore, improving
85	outcomes in young adults with stroke is important, especially given the potential
86	socioeconomic impact due to their longer life expectancy.
87	However, there have been concerns that young adults with ischemic stroke may not
88	receive optimal treatment. Young patients were more likely to be unaware of risk factors
89	prior to experiencing ischemic stroke, <sup>4</sup> to present at the hospital later after stroke onset, <sup>5</sup> and
90	to receive thrombolysis later. <sup>6</sup> Another issue is the lack of specific treatment guidelines for
91	young patients, despite the differing risk factors and causes compared to older patients. <sup>7,8</sup>
92	Over the past 15 years, substantial advancements have been made in acute
93	reperfusion therapy and secondary preventive treatment for ischemic stroke. <sup>9–12</sup> However, the
94	real-world impact of these advancements on clinical outcomes, particularly in young patients,
95	has not been thoroughly explored for more recent period since the early 2010s. While stroke
96	in young adults is gaining increasing attention, data regarding the impact of recent treatment
97	advances on this population remain limited. Prior investigations have often been constrained
98	by cross-sectional designs, <sup>13,14</sup> small sample sizes, <sup>15,16</sup> or timing that predated the
99	introduction of more advanced treatments. <sup>13,16,17</sup>

5

R1/ 6

100	In this study, we aim to fill these gaps by examining trends in the application of
101	advanced treatments and the subsequent clinical outcomes for young stroke patients from
102	2011 to 2019 using data from a multicenter stroke registry in South Korea.
103	

104 Methods

## 105 **Study Population**

106 This retrospective analysis was based on data from a prospective, multicenter stroke

107 registry - the Clinical Research Collaboration for Stroke in Korea-National Institutes of

108 Health (CRCS-K-NIH) registry. The CRCS-K-NIH is a web-based registry implemented in

109 2008 to register patients with acute stroke or transient ischemic attack admitted to the 17

110 participating stroke centers in South Korea. Detailed information on the CRCS-K-NIH

111 registry is provided elsewhere.<sup>18,19</sup> The following inclusion criteria applied: age 18–50 years

112 at presentation, diagnosis of AIS defined as the presence of ischemic symptoms for over 24 h

113 or a relevant ischemic lesion on diffusion-weighted MRI, arrival within seven days from

114 when the stroke symptoms were recognized by the patient (first abnormal time [FAT]), and

115 hospitalization between April 2008 and December 2019.

116

#### 117 **Ethics Statement**

The local institutional review boards (IRBs) of all participating centers of the CRCS-K-NIH registry approved the collection of clinical data to 'monitor and improve the quality and outcomes of stroke care.' Given the de-identified nature of the data and the minimal risk to the participants, the necessity for informed consent was waved. Furthermore, approval to use the registry database was secured from all necessary IRBs (B-2112-728-102).

R1/ 7

123

## 124 Data Collection

125	Information on demographics, risk factors, blood pressure, laboratory data,
126	premorbid disability (modified Rankin scale [mRS]), initial National Institute of Health
127	Stroke Scale (NIHSS), stroke subtype according to the Trial of Org 10172 in Acute Stroke
128	Treatment (TOAST) criteria with some modifications, <sup>20</sup> FAT, last known well time (LKW),
129	diagnostic evaluations, reperfusion therapies, door-to-needle time (DNT), door-to-puncture
130	time (DPT), and discharge medications were obtained from the registry database. Risk factors
131	were dichotomized into two categories: "newly diagnosed" and "previously known or aware,"
132	and the "aware" category was further divided into "on medication" and "not on medication"
133	based on the treatment status.
134	As part of a program aimed at monitoring and improving the quality of stroke care
135	and outcomes, functional outcomes, and occurrence of clinical events, including recurrent
136	stroke and death, were prospectively captured at discharge, 3 months, and 1 year after the
137	index stroke through a structured telephone interview conducted by experienced nurse
138	coordinators or a direct interview by treating physicians at outpatient clinics according to
139	predetermined protocols.
140	Functional outcomes were evaluated using the mRS and were divided into two
141	categories: mRS scores of 0–1 vs. 2–6 and 0–2 vs. 3–6, or treated as an ordinal variable. We
142	also analyzed the occurrence of clinical events, including the time from index stroke onset to
143	recurrent stroke and to death, respectively. Regarding these time-to-event data, patients were

144 censored if they were lost to follow-up or at 1.5 years from the onset of stroke. The

145 operational definitions of all variables are listed in Table S1.

146

R1/ 8

### 147 Statistics

148	We described demographics, risk factors, stroke characteristics, diagnostic
149	evaluations, and treatments across four epochs: 2008–2010, 2011–2013, 2014–2016, and
150	2017–2019. For trend analyses, the ANOVA linear contrast test was applied to continuous
151	variables, and the Cochrane-Armitage test was applied to categorical variables. The Mantel-
152	Haenszel chi-square test was used to treat the 3-month mRS as an ordinal variable. The
153	Kaplan-Meier product limit method was implemented to estimate mortality and cumulative
154	incidence of recurrent strokes, which were subsequently compared across the epochs using a
155	log-rank linear contrast test. Among the 63 variables used in the study, 20 variables were
156	found to have one or more missing values, resulting in an overall missing rate of 0.49%.
157	These missing values were removed pairwise during the tabulation and analysis.
158	Stroke outcomes were analyzed with and without adjustment. Variables for
159	adjustment were predetermined as follows: sex and age for all outcome (Model 1), sex, age,
160	and initial NIHSS score for 3-month mRS score and mortality, and sex, age, stroke risk
161	factors, and stroke subtypes for recurrent stroke (Model 2). For trend analyses in
162	multivariable models, a linear contrast test was applied to binary outcomes in logistic
163	regression models, to survival outcomes in Cox proportional hazard models, and to the whole
164	scale of 3-month mRS scores in an ordinal logistic regression model. Secular trends were
165	analyzed according to age (18-30, 31-40, and 41-50 years) and sex subgroups and presented
166	if needed. Furthermore, secular trends in treatments and outcomes were demonstrated in
167	subgroups of potential contributing factors.
168	A two-tailed <i>p</i> -value of <0.05 was considered statistically significant. All analyses
169	were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R software
170	version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

R1/ 9

171

### 172 Data Availability

173 The data used in this study may be made available upon request to the corresponding author.

174

### 175 **Results**

#### 176 **Demographics, Risk Factors, and Subtypes of Ischemic Stroke (Table 1)**

177 Of 70,567 patients (age 68.3±13.0 years; men 58.5%) registered with AIS between

178 2008 and 2019, 7,050 participants aged 18–50 (10.0%) were selected. Over the 12 years, the

179 proportion of men decreased slightly from 74% to 71% ( $p_{trend}=0.10$ ), but it remained more

180 than twice that of women. The mean age decreased in both sexes, although this change was

181 statistically significant only in women. The decrease in mean age in women was attributable

to an increase in the proportion of women aged 18–30 (Figure 1).

183 Regarding traditional vascular risk factors, we observed significant trends in smoking

and obesity. Current smoking decreased by 13.5% in men but increased by 2.5% in women.

185 Obesity (body mass index  $\geq$  30 kg/m<sup>2</sup>) more than doubled in men (5.2% in 2008-10 to 13.1%

186 in 2017-19). The increase was somewhat less dramatic in women (5.4% to 9.2%). However,

187 no significant trends were observed regarding hypertension, diabetes mellitus, and

188 hyperlipidemia. Awareness and treatment rates of hypertension, diabetes, and hyperlipidemia

189 before the index stroke remained unchanged except for increased awareness of

190 hyperlipidemia.

191 Regarding ischemic stroke subtypes, large artery atherothrombosis (LAA) was the
192 most common etiology, followed by small vessel occlusion (SVO) or undetermined etiology
193 (UDE; depending on the epoch). Notably, other determined etiology (ODE) increased by

R1/ 10

194	9.0%, but LAA, SVO, and cardioembolic stroke (CES) decreased by 2.5%, 5.1%, and 4.3%,
195	respectively. Among ODEs, arterial dissection was the most common, followed by intrinsic
196	diseases of the arterial wall, such as Moyamoya disease and fibromuscular dysplasia (Table
197	S2). Arterial dissection significantly increased in both men and women by 4.7% and 5.1%,
198	respectively. The proportion of UDEs remained unchanged throughout the study period.
199	
200	Clinical Presentation and Treatments (Tables 2)
201	Over the 12 years, the onset-to-door time (ODT) remained unchanged; the median
202	FAT-to-door ranged between 8.0 and 9.4h, and the median LKW-to-door between 11.1 and
203	12.5h. Overall, the proportion of patients hospitalized within 3.5h from LKW was 27.5%.
204	However, initial stroke severity decreased significantly, with a reduction in the mean NIHSS
205	score and the proportion of severe strokes (NIHSS score 16-42) by 0.8 points and 1.9%,
206	respectively.
207	The IVT rate increased by 3.8% between the first two epochs but plateaued afterward.
208	The DNT followed a similar pattern. The overall increase in IVT rate may be attributed to the
209	rise in IVT rate in patients arriving between 3.0 and 4.5 hours from the LKW (from 5.8% in
210	2008–2010 to 21.1% in 2017–2019) and in those with severe stroke (from 27.9% to 47.3%;
211	Tables S3 and S4). However, it should be noted that the IVT rate remained low in patients
212	arriving after 4.5 h from the LKW and in those with mild stroke (2.4% and 5.0% in 2017–
213	2019, respectively).
214	Over the 12 years, the MT rate almost tripled (from 3.2% to 9.2%), but the DPT did
215	not improve. The increase in the MT rate was evident in patients arriving within 6 hours or
216	between 6 and 12 hours of symptom onset and in those with moderate (NIHSS score 5-15) or
217	severe stroke (Tables S3 and S4). However, it should be noted that the MT rates in patients

R1/ 11

218	arriving after 12 l	hours and in those with	mild stroke remained	l low (2.1% and	1 1.9% in 2017–
-----	---------------------	-------------------------	----------------------	-----------------	-----------------

219 2019, respectively).

241

220	Regarding secondary preventive treatments, the overall use of DAPT and DAPT in
221	mild noncardioembolic stroke increased by 20.3% and 22.2%, respectively. The overall use
222	of statins and the use of statins in LAA also increased by 19.7% and 19.2%, respectively.
223	However, the overall use of anticoagulants and anticoagulants in atrial fibrillation decreased
224	by 7.2% and 6.4%, respectively. Among types of anticoagulants in patients with atrial
225	fibrillation, DOAC surpassed warfarin in the last epoch. Reimbursement for DOAC use in
226	patients with atrial fibrillation was introduced by the Korean government in mid-2015. It
227	should be mentioned that in ODEs, the use of anticoagulants decreased by 29.7%, and the use
228	of DAPT increased by 20.3% (Table S5).
229	The clinical presentation and treatment trends did not change noticeably in subgroup
230	analyses according to age group (not presented here) and sex (Table S6).
231	
232	Clinical Outcomes (Table 3)
233	We obtained information on clinical outcomes from 6,057 patients registered since
234	2011. The median follow-up duration was 367 days (interquartile range, 356-381 days). Out
235	of these patients, 5861 (97.9%) had follow-up information post-discharge on time-to-event
236	data, and 5809 (95.9%) had 3-month mRS scores. No significant difference was observed
237	between patients with and without 3-month scores, except for a 1-point lower initial NIHSS
238	median score, a higher prevalence of hypertension, and increased use of discharge statin
239	among the former group (Table S8).
240	In-hospital death, the proportions of 3-month mRS scores 0–1 and mRS scores 0–2,

and mortality did not exhibit significant trends before and after adjusting for age, sex, and

242	initial NIHSS score. However, ordinal logistic regression revealed a significant increasing
243	trend across the whole range of 3-month mRS scores after adjustments (common odds ratio,
244	1.18; 95% confidence interval, 1.04–1.33).
245	Further analyses were conducted to identify factors contributing to the lack of
246	improvement in functional outcomes despite improvement in treatments. The proportion of
247	mRS scores 0-1 increased in patients who underwent MT and those with severe strokes (from
248	33.7% to 47.8% and from 13.2% to 25.0%, respectively; Tables S9 and S10). However, the
249	proportion of mRS scores 0-2 and the mortality did not demonstrate significant
250	improvements in these subgroups.
251	The one-year cumulative incidence of recurrent stroke demonstrated a minor increase
252	from 4.13% in 2011–2013 to 5.47% in 2017–2019 (p=0.04). However, this trend became
253	non-significant in both a minimal model adjusting for age and sex and in the model adjusting
254	for sex, age, stroke risk factors, and stroke subtypes. As post-hoc analysis, pairwise
255	comparisons were made between the three epochs. Notably, the increase in stroke recurrence
256	between 2014-16 and 2017-19 remained significant after Bonferroni adjustment (p=0.01).
257	However, the increase between 2011-13 and 2014-16, or 2011-13 and 2017-19 was no longer
258	significant (p=0.90 and p-0.12, respectively).
259	Figure 2 demonstrates the incidence of recurrent stroke according to the index stroke
260	subtypes. The increase in the stroke recurrence rate was observed in CES, ODE and UDE. In
261	subgroup analysis of ischemic stroke subtype, the cumulative incidence of recurrent stroke
262	increased significantly only in CES and UDE ( $p_{trend} = 0.02$ and $p_{trend} = 0.03$ , respectively,
263	Table S11). Notably, in the CES group, patients who took warfarin had a lower recurrence
264	rate than those who did not (Figure S1, p=0.14 on a log-rank test). In the ODE group, there

R1/ 12

#### R1/ 13

was no difference in stroke recurrence between patients who took warfarin and those who didnot (Figure S2).

267

## 268 **Discussion**

269	In our nationwide cohort of young adults with AIS, parameters regarding advanced
270	treatments such as IVT and MT rates, DNT, and secondary preventive treatments, including
271	DAPT for mild noncardioembolic stroke, DOAC for atrial fibrillation, and statin for LAA,
272	improved over the 12 years. However, the 3-month mRS score, 1-year mortality, and 1-year
273	stroke recurrence rate did not improve. The stroke recurrence rate even increased in the last
274	epoch, which was attributed to increased recurrence in patients with CES, ODE, or UDE.
275	In our study, the functional outcomes at 3 months post-AIS in young adults did not
276	improve and even showed signs of worsening after adjusting for age, sex, and initial stroke
277	severity. The proportion of mRS scores 0-2 was 84% in our study, which aligns with the
278	percentages reported from the late 1990s to mid 2010s in studies of young patients with
279	ischemic stroke (84–94%). <sup>13,14,16</sup> Interestingly, some countries have observed improvement in
280	functional outcomes over the last two decades in the ischemic stroke population across all
281	ages. <sup>11,21–23</sup> Increased proportions of 3-month mRS scores 0–2 were reported in China (from
282	37% in 2002 to 71% in 2016) and Spain (from 49% in 2008 to 55% in 2016). <sup>21,22</sup> The Riks-
283	Stroke registry and Get With The Guideline Stroke data also demonstrated improving trend in
284	discharge to home as a surrogate measure of functional outcome. <sup>11,23</sup>
285	The unchanged trend in functional outcomes despite the enhanced provision of
286	treatments may be attributed to a ceiling effect; the majority of young patients were already
287	functionally independent in the early epoch (3-month mRS scores 0-2, 83.5% in 2011-2013).

R1/ 14

288	On the other hand, the IVT rate and DNT have not shown significant improvement between
289	2011-2013 and 2017-2019 (13.3% vs. 13.8% and 40 min vs. 39 min, respectively). This
290	indicates that patients who could potentially benefit from IVT may not receive optimal
291	treatment, as the hospital arrival time from the onset of stroke (ODT) has remained relatively
292	stagnant. In addition, even though the MT rate has doubled, the number of patients benefiting
293	from this therapy is still limited, accounting for less than 10% of AIS patients even in 2017-
294	19.

population, such as enhancing awareness and treatment of risk factors. This may have a more substantial impact on improving outcomes than merely extending the reach of reperfusion therapy. It is worth noting that only half of our study subjects with known hypertension or diabetes were received medication before their index stroke. Recent studies have underscored that vascular risk factors in young adults are often undertreated, partly because the current treatment thresholds for these risk factors may underestimate the actual risk of stroke in this younger population.<sup>2</sup>

Thus, more emphasis should be placed on areas that would benefit a larger

295

We demonstrated that the stroke recurrence rate among young patients did not decrease and was even highest in the last epoch. This finding contrasts the decreasing trend observed among young adults with AIS in Sweden<sup>16</sup> and the AIS population across all ages in the United States before the early 2010s.<sup>25</sup> The apparent increase in stroke recurrence in the last epoch might be influenced by a low number of events and potential changes in the study population characteristics over time. Further studies in other populations are needed to ascertain if this trend may be replicated.

In an attempt to discern potential factors contributing to the highest stroke recurrence
rate in the most recent epoch, we scrutinized changes in risk factors, stroke subtypes, and

R1/ 15

312	preventive treatments across all epochs. Over the 12 years, we identified three significant
313	changes: a doubling in the prevalence of obesity, an increase in ODE among ischemic stroke
314	subtypes, and a decrease in the use of warfarin (Tables 1, 2, and Table S5). The increase in
315	obesity in young adults is consistent with trends seen in several developed countries,
316	including the United States and South Korea. <sup>25–27</sup> However, it is worth noting that the
317	increase in the prevalence of obesity in young stroke patients was slightly steeper than that
318	found in the general population of young adults according to data from the Korean National
319	Health Insurance Service (from 4.0% to 8.5% between 2009 and 2019). <sup>25</sup>
320	The changes in the usage patterns of antithrombotic therapies might have played a
321	role in the stagnant trend in stroke recurrence rates among young patients. We observed a
322	decline in the use of warfarin among patients with CES, ODE, and UDE, with a reduction of -
323	24.3%, -17.8%, and -7.3%, respectively, between 2011-13 and 2017-19. Interestingly, these
324	are the same three subtypes that exhibited increased stroke recurrence in the most recent
325	epoch (Figure 2, Table S5, and Table S11). Additionally, a lower recurrence rate was found
326	in CES patients on warfarin than those on other antithrombotic therapies (Figure S1).
327	Guidelines specific to young patients with CES and no atrial fibrillation, ODE, or UDE are
328	not well-established. <sup>8</sup> In some patients with congenital or valvular heart disease, warfarin
329	may be superior to antiplatelets or DOACs by blocking several coagulation pathways
330	simultaneously. <sup>28</sup> Further research is warranted to verify the recent increase in stroke
331	recurrence in young adults and the influence of warfarin use.
332	Over the 12 years, the mean age of young patients with AIS decreased, which was
333	attributed to an increase in the proportion of the youngest group (women, 18-30 years)
334	(Figure 1B). A recent systematic review reported that the risk of stroke was higher in young
335	women (15–35 years) than in young men. <sup>29</sup> However, despite the increasing trend in the

R1/ 16

336	proportion of women in our study, there were more men. A preponderance of young male
337	patients with stroke has been reported in other studies from Asian countries. <sup>30</sup>

338 This study has several limitations. Firstly, most participating hospitals in our registry 339 are either university hospitals or regional stroke centers, which may not necessarily represent 340 the entirety of acute stroke care hospitals in South Korea. However, it is noteworthy that the 341 demographics and baseline characteristics in our study do not significantly deviate from a 342 previous study that relied on national claims data,<sup>31</sup> which includes 98–99% of the total 343 Korean population. Secondly, there was an increase in the number of hospitals participating 344 in our registry throughout the study period. This could have potential implications for secular 345 trend analysis and should be considered when interpreting our results as certain factors (e.g., 346 socioeconomic status) could change over time. Thirdly, given the retrospective nature of our 347 data collection and the descriptive study design, we could not establish causal relationship 348 between treatments and outcomes. Fourthly, we could not determine the causal relationship 349 between treatments and outcomes due to the retrospective nature of data collection and the 350 descriptive study design. Fifthly, since we started to collect outcome data in 2011, we could 351 only analyze the trends in outcomes during the last three epochs. Our findings of an increase 352 in stroke recurrence in the last epoch could be due to chance; however, this finding may 353 warrant further studies with a more extended observation period. Lastly, our study was based 354 on a nationwide stroke registry in South Korea. Therefore, the generalizability of our findings 355 to other countries and ethnicities is limited.

In summary, clinical outcomes of young adults with AIS in South Korea did not improve between 2011 and 2019 despite increased delivery of AIS and recurrent preventive treatments. Potential areas of improvement to close the clinical gap include early detection and treatment of traditional risk factors, expanded implementation of reperfusion therapy,

#### R1/ 17

360 reduction in delays	in the administration	of reperfusion therapy,	, and establishment of optimal
-------------------------	-----------------------	-------------------------	--------------------------------

- antithrombotic strategies in young patients with CES, ODE, and UDE.
- 362

## 363 Sources of Funding:

- 364 This study was supported in part by the Korea Centers for Disease Control and Prevention
- 365 (no. 2020ER620200f).
- 366 Disclosures:
- 367 H-J Bae reports grants from Astrazeneca, Bayer Korea, Bristol Myers Squibb Korea, Dong-A
- 368 ST, Jeil Pharmaceutical Co., Ltd., Samjin Pharm, Takeda Pharmaceuticals Korea Co., Ltd.,
- 369 and Yuhan Corporation, roles as a principal investigator or co-investigator of clinical trials
- 370 sponsored by Bayer, Bristol Myers Squibb, GNT Pharma, Korean Drug Co., Ltd., Shinpoong
- 371 Pharm. Co., Ltd., and person fees from Amgen Korea, Bayer, Daiichi Sankyo, JW
- 372 Pharmaceutical, Hanmi Pharmaceutical Co., Ltd., Otsuka Korea, SK chemicals, and Viatris
- 373 Korea, outside the submitted work.

R1/ 18

# 374 **References**

- 1. Béjot Y, Daubail B, Jacquin A, Durier J, Osseby G-V, Rouaud O, Giroud M. Trends in the
  incidence of ischaemic stroke in young adults between 1985 and 2011: the Dijon Stroke
  Registry. *J Neurology Neurosurg Psychiatry*. 2014;85:509.
- 378 2. Scott CA, Li L, Rothwell PM. Diverging Temporal Trends in Stroke Incidence in Younger
  379 vs Older People. *Jama Neurol.* 2022;79.
- 380 3. Khan SU, Khan MZ, Khan MU, Khan MS, Mamas MA, Rashid M, Blankstein R, Virani
- 381 SS, Johansen MC, Shapiro MD, et al. Clinical and Economic Burden of Stroke Among
- 382Young, Midlife, and Older Adults in the United States, 2002-2017. Mayo Clin Proc
- 383 Innovations Qual Outcomes. 2021;
- 4. Sung S, Lai EC, Wu DP, Hsieh C. Previously undiagnosed risk factors and medication
  nonadherence are prevalent in young adults with first□ever stroke. *Pharmacoepidem Dr S*.
- 386 2017;26:1458–1464.
- 5. Leung LY, Caplan LR. Factors Associated with Delay in Presentation to the Hospital for
  Young Adults with Ischemic Stroke. *Cerebrovasc Dis.* 2016;42:10–14.
- 6. Dodds JA, Xian Y, Sheng S, Fonarow GC, Bhatt DL, Matsouaka R, Schwamm LH,
- Peterson ED, Smith EE. Thrombolysis in young adults with stroke: Findings from Get With
   The Guidelines–Stroke. *Neurology*. 2019;92:e2784–e2792.
- 392 7. Ekker MS, Boot EM, Singhal AB, Tan KS, Debette S, Tuladhar AM, Leeuw F-E de.
- 393 Epidemiology, aetiology, and management of ischaemic stroke in young adults. *Lancet*
- 394 Neurology. 2018;17:790–801.
- 395 8. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J,
- 396 Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the Early Management of Patients
- 397 With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
- 398 of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American
- Heart Association/American Stroke Association. *Stroke*. 2019;50:e344–e418.
- 400 9. Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, Kamiyama K,
- 401 Yazawa Y, Kawada S, Sasaki M, et al. Twenty-Year Change in Severity and Outcome of
  402 Ischemic and Hemorrhagic Strokes. *Jama Neurol.* 2022;79:1–9.
- 10. Lee M, Wu Y-L, Ovbiagele B. Trends in Incident and Recurrent Rates of First-Ever
  Ischemic Stroke in Taiwan between 2000 and 2011. *J Stroke*. 2015;18:60–65.
- 405 11. Appelros P, Jonsson F, Åsberg S, Asplund K, Glader E-L, Åsberg KH, Norrving B,
- 406 Stegmayr B, Terént A, Collaboration R-S. Trends in Stroke Treatment and Outcome between
- 407 1995 and 2010: Observations from Riks-Stroke, the Swedish Stroke Register. *Cerebrovasc*
- 408 Dis. 2014;37:22–29.

R1/ 19

- 409 12. Modig K, Talbäck M, Ziegler L, Ahlbom A. Temporal trends in incidence, recurrence and
- 410 prevalence of stroke in an era of ageing populations, a longitudinal study of the total Swedish
- 411 population. BMC Geriatr. 2019;19:31.
- 412 13. Neau J-P, Ingrand P, Mouille-Brachet C, Rosier M-P, Couderq C, Alvarez A, Gil R.
- 413 Functional Recovery and Social Outcome after Cerebral Infarction in Young Adults.
- 414 *Cerebrovasc Dis.* 1998;8:296–302.
- 415 14. Simonetti BG, Mono M-L, Huynh-Do U, Michel P, Odier C, Sztajzel R, Lyrer P, Engelter
- 416 ST, Bonati L, Gensicke H, et al. Risk factors, aetiology and outcome of ischaemic stroke in
- 417 young adults: the Swiss Young Stroke Study (SYSS). *J Neurol*. 2015;262:2025–2032.
- 418 15. Synhaeve NE, Arntz RM, Maaijwee NAM, Rutten-Jacobs LCA, Schoonderwaldt HC,
- 419 Dorresteijn LDA, Kort PLM de, Dijk EJ van, Leeuw F-E de. Poor Long-Term Functional
- 420 Outcome After Stroke Among Adults Aged 18 to 50 Years. *Stroke*. 2014;45:1157–1160.
- 421 16. Varona JF, Bermejo F, Guerra JM, Molina JA. Long-term prognosis of ischemic stroke in
  422 young adults. *J Neurol*. 2004;251:1507–1514.
- 423 17. Giang KW, Björck L, Ståhl CH, Nielsen S, Sandström TZ, Jern C, Torén K, Rosengren A.
- Trends in risk of recurrence after the first ischemic stroke in adults younger than 55 years of age in Sweden. *Int J Stroke*. 2015;11:52–61.
- 426 18. Park TH, Lee J-K, Park M-S, Park S-S, Hong K-S, Ryu W-S, Kim D-E, Park MS, Choi
- 427 K-H, Kim J-T, et al. Neurological Deterioration in Patients with Acute Ischemic Stroke or
- 428 Transient Ischemic Attack. *Neurology*. 2020;95:10.1212/WNL.000000000010603.
- 429 19. Bae H-J, Kim JY, Kang J, Kim BJ, Han M-K, Choi K-H, Kim J-T, Park M-S, Cho K-H,
- 430 Kim BK, et al. David G. Sherman Lecture Award: 15-Year Experience of the Nationwide
- 431 Multicenter Stroke Registry in Korea. *Stroke*. 2022;101161STROKEAHA122039212.
- 432 20. Ko Y, Lee S, Chung J-W, Han M-K, Park J-M, Kang K, Park TH, Park S-S, Cho Y-J,
- Hong K-S, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. J *Stroke*. 2014;16:161–172.
- 435 21. Rodríguez-Castro E, López-Dequit I, Santamaría-Cadavid M, Arias-Rivas S, Rodríguez-
- 436 Yáñez M, Pumar JM, Hervella P, López-Arias E, Silva-Candal A da, Estany A, et al. Trends
- 437 in stroke outcomes in the last ten years in a European tertiary hospital. *Bmc Neurol*.
- 438 2018;18:164.
- 439 22. Liu J, Zheng L, Cheng Y, Zhang S, Wu B, Wang D, Zhang S, Tao W, Wu S, Liu M.
- 440 Trends in Outcomes of Patients With Ischemic Stroke Treated Between 2002 and 2016.
- 441 *Circulation Cardiovasc Qual Outcomes*. 2019;12:e005610.
- 442 23. Song S, Fonarow GC, Olson DM, Liang L, Schulte PJ, Hernandez AF, Peterson ED,
- 443 Reeves MJ, Smith EE, Schwamm LH, et al. Association of Get With The Guidelines-Stroke

R1/ 20

- 444 Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic
  445 Stroke. 2018;47:1294–1302.
- 446 24. Sozener CB, Lisabeth LD, Shafie-Khorassani F, Kim S, Zahuranec DB, Brown DL,
- 447 Skolarus LE, Burke JF, Kerber KA, Meurer WJ, et al. Trends in Stroke Recurrence in
- 448 Mexican Americans and Non-Hispanic Whites. *Stroke*. 2020;51:2428–2434.
- 449 25. Nam GE, Kim Y-H, Han K, Jung J-H, Rhee E-J, Lee W-Y, Obesity OFS of the KS for the
- 450 S of. Obesity Fact Sheet in Korea, 2020: Prevalence of Obesity by Obesity Class from 2009
- 451 to 2018. J. Obes. Metab. Syndr. 2021;30:141–148.
- 452 26. George MG, Tong X, Kuklina EV, Labarthe DR. Trends in stroke hospitalizations and
- associated risk factors among children and young adults, 1995–2008. *Ann Neurol.*
- 454 2011;70:713–721.
- 455 27. Ellison-Barnes A, Johnson S, Gudzune K. Trends in Obesity Prevalence Among Adults
  456 Aged 18 Through 25 Years, 1976-2018. *JAMA*. 2021;326:2073–2074.
- 28. Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR, Earing MG,
  Ghoshhajra BB, Karamlou T, et al. Congenital Heart Disease in the Older Adult. *Circulation*.
- 459 2015;131:1884–1931.
- 460 29. Leppert MH, Burke JF, Lisabeth LD, Madsen TE, Kleindorfer DO, Sillau S, Schwamm
- LH, Daugherty SL, Bradley CJ, Ho PM, et al. Systematic Review of Sex Differences in
- 462 Ischemic Strokes Among Young Adults: Are Young Women Disproportionately at Risk?463 *Stroke*. 53:319–327.
- 464 30. Jacob MA, Ekker MS, Allach Y, Cai M, Aarnio K, Arauz A, Arnold M, Bae H-J, Bandeo
- 465 L, Barboza MA, et al. Global Differences in Risk Factors, Etiology, and Outcome of
- 466 Ischemic Stroke in Young Adults—A Worldwide Meta-analysis. *Neurology*. 2022;98:e573–
- 467 e588.
- 468 31. Kim JY, Kang K, Kang J, Koo J, Kim D-H, Kim BJ, Kim W-J, Kim E-G, Kim JG, Kim
- 469 J-M, et al. Executive Summary of Stroke Statistics in Korea 2018: A Report from the
- 470 Epidemiology Research Council of the Korean Stroke Society. *J Stroke*. 2018;21:42–59.
- 471
- 472
- 473
- 474

R1/ 21

# 475 **Tables**

Variables		2008–2010 (n=993)	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	p for trend
Men		73.7%	72.4%	71.0%	71.3%	0.10
Mean age (SD), years	All	43.6 (6.1)	43.2 (6.6)	43.1 (6.4)	42.9 (6.9)	0.009
-	Men	43.7 (5.9)	43.5 (6.4)	43.3 (6.3)	43.3 (6.4)	0.14
	Women	43.5 (6.6)	42.3 (7.0)	42.6 (6.8)	42.0 (7.8)	0.02
Risk factors						
Current smoking	All	53.1%	50.5%	47.6%	42.8%	< 0.001
C	Men	68.2%	65.3%	62.5%	54.7%	< 0.001
	Women	10.7%	11.8%	10.9%	13.2%	0.32
Obesity (BMI $\geq$ 30 kg/m <sup>2</sup> )	All	5.2%	7.2%	10.5%	12.0%	< 0.001
C ,	Men	5.2%	7.1%	10.6%	13.1%	< 0.001
	Women	5.4%	7.7%	10.1%	9.2%	0.053
Hypertension	All	43.2%	43.7%	40.6%	43.4%	0.77
• •	Men	47.0%	46.9%	43.9%	47.4%	0.99
	Women	32.6%	35.2%	32.4%	33.3%	0.83
Aware <sup>†</sup>		81.4%	76.9%	80.8%	78.4%	0.69
On medication <sup>‡</sup>		60.7%	63.7%	54.6%	63.7%	0.85
Diabetes mellitus	All	20.8%	20.0%	19.8%	20.9%	0.81
	Men	22.1%	20.7%	21.4%	22.4%	0.56
	Women	17.2%	18.2%	16.0%	17.1%	0.70
Aware <sup>†</sup>		72.9%	74.6%	74.4%	73.2%	0.91
On medication <sup>‡</sup>		72.8%	72.5%	68.3%	72.1%	0.73
Hyperlipidemia	All	25.2%	28.8%	25.9%	27.0%	0.91
	Men	26.6%	31.5%	28.6%	30.0%	0.48
	Women	21.1%	21.5%	19.2%	19.7%	0.43
Aware		35.6%	38.9%	48.1%	51.3%	< 0.001
On medication <sup>‡</sup>		60.7%	62.8%	53.1%	64.1%	0.66
Atrial fibrillation	All	6.0%	5.0%	4.9%	4.3%	0.04
	Men	5.2%	4.3%	5.2%	4.3%	0.61
±	Women	8.4%	6.8%	4.0%	4.2%	0.003
Aware <sup>†</sup>		61.7%	47.1%	50.0%	42.7%	0.0496
On medication <sup>‡</sup>		32.4%	34.2%	40.0%	43.9%	0.24
Ischemic stroke subt	ypes					
Large artery atherosclerosis	All	30.8%	33.5%	30.4%	28.3%	0.008
	Men	32.5%	35.0%	31.6%	30.0%	0.03
	Women	26.1%	29.6%	27.4%	24.0%	0.17
Small vessel occlusion	All	26.8%	22.9%	22.1%	21.7%	0.004
	Men	28.3%	25.2%	24.2%	22.9%	0.01
	Women	22.6%	16.8%	16.8%	18.8%	0.48
Cardioembolic stroke	All	14.0%	11.0%	11.2%	9.7%	0.001
	Men	12.8%	9.3%	10.4%	9.2%	0.05
	Women	17.2%	15.5%	13.3%	10.9%	0.01
Other determined etiology	All	8.6%	10.4%	12.9%	17.6%	< 0.001

## 476 **Table 1** Secular Trends in Demographics, Risk Factors, and Subtypes of Ischemic Stroke

R1/ 22

	Men	7.9%	9.4%	10.4%	16.0%	< 0.001
	Women	10.3%	13.0%	19.2%	21.6%	< 0.001
Undetermined etiology	All	19.8%	22.3%	23.4%	22.6%	0.11
	Men	18.5%	21.1%	23.2%	21.9%	0.07
	Women	23.7%	25.1%	23.3%	24.8%	0.90

477 Values are percentages unless indicated otherwise.

478 \* p for trend by Cochran-Armitage trend test for categorical and by ANOVA linear contrast test for continuous

479 variables.

480 <sup>†</sup> Proportion of preexisting risk factors among all patients diagnosed with the risk factor during index stroke

481 admission.

482 <sup>‡</sup> Proportion of patients who had been prescribed medicine for the risk factor among those diagnosed with the

483 risk factor before index stroke.

484 BMI, body mass index.

485

R1/ 23

486	Table 2 Secular Trends in Clinical Presentation and Treatments
-----	--

Variables	2008–2010 (n=993)	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	<i>p</i> for trend <sup>*</sup>
Onset-to-door time	(	()	()	(, )	
Median FAT-to-door (IQR), h	8.4 (1.9–29.5)	8.2 (2.4–33.5)	9.4 (2.1–33.6)	8.0 (2.0–31.6)	0.66
Median LKW-to-door (IQR), h	11.7 (2.8– 32.7)	11.1 (3.0–37.1)	12.5 (3.1–38.7)	11.4 (2.8–34.6)	0.62
LKW-to-door within 3.5h	27.7%	27.8%	26.5%	28.1%	0.92
Stroke severity					
Mean initial NIHSS score (SD)	4.8±5.5	4.2±5.3	4.2±5.1	4.0±4.9	< 0.001
Median initial NIHSS score (IQR)	3 (1–6)	2 (1-5)	2 (1–5)	2 (1–5)	< 0.001
Mild stroke (≤4)	64.9%	71.0%	70.7%	69.8%	0.06
Moderate stroke (5–15)	28.3%	23.4%	24.0%	25.3%	0.39
Severe stroke (16–42)	6.8%	5.6%	5.4%	4.9%	0.03
Reperfusion therapy					
IVT rate	9.5%	13.3%	14.0%	13.8%	0.004
Median DNT (IQR), min	58 (43-83)	40 (31–54)	37 (26.8–49)	39 (29–55.8)	< 0.001
DNT ≤60 min	56.2%	84.2%	86.3%	81.5%	< 0.001
MT rate	3.2%	5.3%	7.5%	9.2%	< 0.001
Median DPT (IQR), min	113 (88–146)	110 (92–137)	115.5 (87.3– 158.5)	106 (85–153.3)	0.84
DPT ≤90 min	26.1%	23.5%	31.2%	30.9%	0.28
Discharge medications					
Dual antiplatelet therapy	26.7%	24.8%	32.8%	47.0%	< 0.001
In noncardioembolic minor stroke	28.6%	25.0%	35.2%	50.8%	< 0.001
Anticoagulation	15.8%	13.1%	9.6%	8.6%	< 0.001
Warfarin	15.2%	11.6%	6.8%	4.3%	< 0.001
DOAC	0.0%	0.2%	2.3%	3.8%	< 0.001
Anticoagulation in AF	78.3%	78.2%	71.0%	71.9%	0.22
Warfarin in AF	75.0%	72.4%	41.0%	14.6%	< 0.001
DOAC in AF	0.0%	4.6%	30.0%	56.2%	< 0.001
Statin	71.5%	79.9%	86.9%	91.2%	< 0.00
Among LAA	76.1%	86.2%	89.8%	95.3%	< 0.001

487 Values are percentages unless indicated otherwise.

488 \* p for trend by Cochran–Armitage trend test for categorical and ANOVA linear contrast test for continuous

490 AF, atrial fibrillation; DNT, door-to-needle time; DOAC, direct oral anticoagulant; DPT, door-to-puncture time;

491 FAT, first abnormal time; IVT, intravenous thrombolysis; LAA, large artery atherosclerosis; LKW, last known

492 well time; MT, mechanical thrombectomy; National Institute of Health Stroke Scale.

<sup>489</sup> variables.

Variables	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	p for trend* Unadjusted	Model 1 <sup>†</sup>	Model 2 <sup>‡</sup>
In-hospital death	0.90%	1.50%	1.00%	0.71	0.23	-
3-month mRS score <sup>§</sup>				0.41	0.16	.007
0	39.9%	37.1%	35.9%			
1	27.3%	30.7%	32.7%			
2	16.3%	16.4%	14.5%			
3	8.5%	8.1%	8.7%			
4	4.0%	3.9%	4.1%			
5	2.0%	1.5%	2.0%			
б	2.0%	2.3%	2.2%			
Mean (SD)	2.23 (1.42)	2.25 (1.40)	2.27 (1.42)			
Median (IQR)	2 (1-3)	2 (1-3)	2 (1-3)			
3-month mRS scores 0–1	67.2%	67.8%	68.6%	0.37	0.40	0.22
3-month mRS scores 0–2	83.5%	84.2%	83.0%	0.64	0.65	0.63
Mortality				0.50	0.57	0.83
30 days	1.59 (0.99-2.18)	1.83 (1.25-2.41)	1.44 (0.94–1.93)			
90 days	1.95 (1.29-2.61)	2.13 (1.50-2.76)	1.89 (1.33-2.46)			
365 days	2.52 (1.77-3.28)	2.93 (2.19-3.68)	2.32 (1.69-2.95)			
Cumulative incidence of re	current strokes			0.04	0.08	0.10
30 days	2.00 (1.33-2.66)	1.59 (1.04-2.14)	2.53 (1.88-3.19)			
90 days	3.34 (2.48-4.21)	2.16 (1.52-2.79)	4.11 (3.28-4.94)			
365 days	4.13 (3.17-5.09)	3.70 (2.86–4.55)	5.47 (4.51–6.44)			

#### 493 Table 3 Secular Trends in Clinical Outcomes of Ischemic Stroke

494 Values are percentages unless indicated otherwise.

495 \* Unadjusted p-values by Mantel-Haenszel chi-square test for 3-month mRS scores, Cochran-Armitage trend test for categorical, ANOVA linear contrast test for continuous

496 variables, and log-rank linear contrast test for survival outcomes, and adjusted p-values by ordinal logistic regression for 3-month mRS score, linear contrast test of logistic

497 regression models for in-hospital death, 3-month mRS scores 0–1 and 0–2, and linear contrast test for Cox proportional hazard models for mortality and recurrent stroke.

498 †Model 1 was adjusted for sex and age.

R1/ 25

- 499 ‡ Model 2 additionally adjusted initial NIHSS for 3-month mRS and mortality, and risk factor and subtype for recurrent stroke.
- 500 §95.9% of patients had 3-month mRS scores
- 501 ||Pairwise comparison was only significant between 2014-16 and 2017-19 with Bonferroni adjustment, p=0.01.
- 502 mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale

R1/ 26

## 503 Figure Legends

- 504 **Figure 1** Trends in Mean Age Between 2008 and 2019
- 505 (A) Mean age according to sex and calendar year, (B) secular changes in age group
- 506 proportions in women, and (C) secular changes in age group proportions in men.
- 507
- 508 **Figure 2** Stroke Recurrence According to Epochs and Stroke Subtypes
- 509 Stroke recurrence in (A) overall, (B) large artery atherosclerosis, (C) small vessel occlusion,
- 510 (D) cardioembolic stroke, (E) other determined etiology, and (F) undetermined etiology.







